{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:29:56Z","timestamp":1761755396552,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22377-5","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:26:07Z","timestamp":1761755167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting LAG3 to alter the tumor immune reactivity of CD8+T cells is a potential therapy for skin cutaneous melanoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Jin","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaozhi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"10400","key":"22377_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E. & Scolyer, R. A. Cutaneous melanoma. Lancet (London England). 402 (10400), 485\u2013502 (2023).","journal-title":"Lancet (London England)"},{"issue":"3","key":"22377_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jaad.2022.04.056","volume":"89","author":"EK Brunsgaard","year":"2023","unstructured":"Brunsgaard, E. K., Wu, Y. P. & Grossman, D. Melanoma in skin of color: part I. Epidemiology and clinical presentation. J. Am. Acad. Dermatol. 89 (3), 445\u2013456 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"12","key":"22377_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/jamadermatol.2021.3884","volume":"157","author":"CG Watts","year":"2021","unstructured":"Watts, C. G. et al. Association between melanoma detected during routine skin checks and mortality. JAMA Dermatology. 157 (12), 1425\u20131436 (2021).","journal-title":"JAMA Dermatology"},{"key":"22377_CR4","doi-asserted-by":"crossref","unstructured":"T\u00edm\u00e1r, J. & Lad\u00e1nyi, A. Molecular pathology of skin melanoma: Epidemiology, differential Diagnostics, prognosis and therapy prediction. Int. J. Mol. Sci. ;23(10). (2022).","DOI":"10.3390\/ijms23105384"},{"key":"22377_CR5","doi-asserted-by":"publisher","first-page":"951247","DOI":"10.3389\/fimmu.2022.951247","volume":"13","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. CXCL11 correlates with immune infiltration and impacts patient immunotherapy efficacy: A Pan-Cancer analysis. Front. Immunol. 13, 951247 (2022).","journal-title":"Front. Immunol."},{"issue":"11","key":"22377_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","volume":"2","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. & Chen, L. Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2 (11), 1403\u20131404 (2016).","journal-title":"JAMA Oncol."},{"issue":"4","key":"22377_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8(+) T cell States in human cancer: insights from single-cell analysis. Nat. Rev. Cancer. 20 (4), 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"22377_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","volume":"77","author":"CG Clemente","year":"1996","unstructured":"Clemente, C. G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (7), 1303\u20131310 (1996).","journal-title":"Cancer"},{"key":"22377_CR9","doi-asserted-by":"crossref","unstructured":"Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & L\u00f3pez-Soto, A. The hallmarks of successful anticancer immunotherapy. Sci. Transl. Med. ;10(459). (2018).","DOI":"10.1126\/scitranslmed.aat7807"},{"key":"22377_CR10","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1038\/s41598-022-14319-2","volume":"12","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Integrated analysis reveals the pivotal interactions between immune cells in the melanoma tumor microenvironment. Sci. Rep. 12, 10040 (2022).","journal-title":"Sci. Rep."},{"issue":"1","key":"22377_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/imm.13588","volume":"168","author":"Y Huang","year":"2023","unstructured":"Huang, Y., Jia, A., Wang, Y. & Liu, G. CD8(+) T cell exhaustion in anti-tumour immunity: the new insights for cancer immunotherapy. Immunology 168 (1), 30\u201348 (2023).","journal-title":"Immunology"},{"key":"22377_CR12","doi-asserted-by":"publisher","first-page":"9164","DOI":"10.1038\/s41598-021-88676-9","volume":"11","author":"Z Wang","year":"2021","unstructured":"Wang, Z. & Peng, M. A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8 T cells. Sci. Rep. 11, 9164 (2021).","journal-title":"Sci. Rep."},{"key":"22377_CR13","doi-asserted-by":"publisher","first-page":"25569","DOI":"10.1038\/s41598-025-10952-9","volume":"15","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. TNFAIP2 deficiency drives formation of an immunosuppressive tumor microenvironment and confers resistance to anti-PD-1 therapy in skin cutaneous melanoma. Sci. Rep. 15, 25569 (2025).","journal-title":"Sci. Rep."},{"issue":"11","key":"22377_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","volume":"21","author":"M Reina-Campos","year":"2021","unstructured":"Reina-Campos, M., Scharping, N. E. & Goldrath, A. W. CD8(+) T cell metabolism in infection and cancer. Nat. Rev. Immunol. 21 (11), 718\u2013738 (2021).","journal-title":"Nat. Rev. Immunol."},{"issue":"17","key":"22377_CR15","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint Blockade in cancer therapy. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 33 (17), 1974\u20131982 (2015).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"issue":"23","key":"22377_CR16","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-21-2390","volume":"28","author":"LP Andrews","year":"2022","unstructured":"Andrews, L. P. et al. Molecular pathways and mechanisms of LAG3 in cancer therapy. Clin. Cancer Research: Official J. Am. Association Cancer Res. 28 (23), 5030\u20135039 (2022).","journal-title":"Clin. Cancer Research: Official J. Am. Association Cancer Res."},{"issue":"8","key":"22377_CR17","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","volume":"22","author":"HM Zarour","year":"2016","unstructured":"Zarour, H. M. Reversing T-cell dysfunction and exhaustion in cancer. Clin. Cancer Research: Official J. Am. Association Cancer Res. 22 (8), 1856\u20131864 (2016).","journal-title":"Clin. Cancer Research: Official J. Am. Association Cancer Res."},{"key":"22377_CR18","doi-asserted-by":"publisher","first-page":"758288","DOI":"10.3389\/fimmu.2021.758288","volume":"12","author":"M Yan","year":"2021","unstructured":"Yan, M. et al. Single-Cell transcriptomic analysis reveals a Tumor-Reactive T cell signature associated with clinical outcome and immunotherapy response in melanoma. Front. Immunol. 12, 758288 (2021).","journal-title":"Front. Immunol."},{"key":"22377_CR19","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"22377_CR20","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"22377_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"22377_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","volume":"38","author":"J Si","year":"2020","unstructured":"Si, J. et al. Hematopoietic progenitor Kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-Based immunotherapies. Cancer cell. 38 (4), 551\u201366e11 (2020).","journal-title":"Cancer cell."},{"issue":"1","key":"22377_CR23","doi-asserted-by":"publisher","first-page":"2080328","DOI":"10.1080\/2162402X.2022.2080328","volume":"11","author":"M Zettl","year":"2022","unstructured":"Zettl, M. et al. Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. Oncoimmunology 11 (1), 2080328 (2022).","journal-title":"Oncoimmunology"},{"issue":"8","key":"22377_CR24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2326-6066.CIR-15-0143","volume":"3","author":"MC Mihm Jr","year":"2015","unstructured":"Mihm, M. C. Jr. & Mul\u00e9, J. J. Reflections on the histopathology of Tumor-Infiltrating lymphocytes in melanoma and the host immune response. Cancer Immunol. Res. 3 (8), 827\u2013835 (2015).","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"22377_CR25","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","volume":"69","author":"H Harlin","year":"2009","unstructured":"Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8\u2009+\u2009T-cell recruitment. Cancer Res. 69 (7), 3077\u20133085 (2009).","journal-title":"Cancer Res."},{"issue":"7739","key":"22377_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-018-0812-9","volume":"565","author":"SL Park","year":"2019","unstructured":"Park, S. L. et al. Tissue-resident memory CD8(+) T cells promote melanoma-immune equilibrium in skin. Nature 565 (7739), 366\u2013371 (2019).","journal-title":"Nature"},{"issue":"4","key":"22377_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ccell.2022.03.006","volume":"40","author":"JR Veatch","year":"2022","unstructured":"Veatch, J. R. et al. Neoantigen-specific CD4(+) T cells in human melanoma have diverse differentiation States and correlate with CD8(+) T cell, macrophage, and B cell function. Cancer Cell. 40 (4), 393\u2013409e9 (2022).","journal-title":"Cancer Cell."},{"issue":"3","key":"22377_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/eji.202048747","volume":"51","author":"ZN Willsmore","year":"2021","unstructured":"Willsmore, Z. N. et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur. J. Immunol. 51 (3), 544\u2013556 (2021).","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"22377_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","volume":"8","author":"AH Sharpe","year":"2007","unstructured":"Sharpe, A. H., Wherry, E. J., Ahmed, R. & Freeman, G. J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8 (3), 239\u2013245 (2007).","journal-title":"Nat. Immunol."},{"issue":"8","key":"22377_CR30","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114 (8), 1537\u20131544 (2009).","journal-title":"Blood"},{"key":"22377_CR31","doi-asserted-by":"publisher","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","volume":"42","author":"E Ruffo","year":"2019","unstructured":"Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J. & Vignali, D. A. A. Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor. Semin. Immunol. 42, 101305 (2019).","journal-title":"Semin. Immunol."},{"key":"22377_CR32","first-page":"269","volume":"344","author":"MV Goldberg","year":"2011","unstructured":"Goldberg, M. V. & Drake, C. G. LAG-3 in cancer immunotherapy. Curr. Top. Microbiol. Immunol. 344, 269\u2013278 (2011).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"22377_CR33","doi-asserted-by":"publisher","first-page":"785091","DOI":"10.3389\/fimmu.2021.785091","volume":"12","author":"AP Shi","year":"2021","unstructured":"Shi, A. P. et al. Immune checkpoint LAG3 and its ligand FGL1 in cancer. Front. Immunol. 12, 785091 (2021).","journal-title":"Front. Immunol."},{"issue":"5","key":"22377_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy, C. et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat. Immunol. 23 (5), 757\u2013767 (2022).","journal-title":"Nat. Immunol."},{"issue":"3","key":"22377_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","volume":"40","author":"A Asrir","year":"2022","unstructured":"Asrir, A. et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 40 (3), 318\u201334e9 (2022).","journal-title":"Cancer Cell."},{"issue":"1","key":"22377_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12967-022-03646-7","volume":"20","author":"D Shao","year":"2022","unstructured":"Shao, D. et al. LAG3 Blockade coordinates with microwave ablation to promote CD8(+) T cell-mediated anti-tumor immunity. J. Translational Med. 20 (1), 433 (2022).","journal-title":"J. Translational Med."},{"key":"22377_CR37","doi-asserted-by":"publisher","first-page":"1514578","DOI":"10.3389\/fonc.2024.1514578","volume":"14","author":"R Wu","year":"2024","unstructured":"Wu, R., Zeng, M., Zhang, Y. & He, J. LAG3 immune inhibitors: a novel strategy for melanoma treatment. Front. Oncol. 14, 1514578 (2024).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22377-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22377-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22377-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:26:08Z","timestamp":1761755168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22377-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22377"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22377-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiments were approved by the Animal Ethics Committee of the Yangtze University. All operating methods were performed in accordance with relevant guidelines and regulations. All methods reported were in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"37910"}}